Actively Recruiting
Artificial Intelligence (AI) Cytopathology Trial
Led by The University of Texas Health Science Center, Houston · Updated on 2023-02-16
50
Participants Needed
1
Research Sites
340 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Purpose The primary objective of the study is to compare interpretation of EUS FNA/FNB samples for adequacy between ROSE and AI at bedside. To compare accuracy of preliminary diagnosis results between ROSE and AI at bedside versus final pathology report. Research design This is a prospective single center study to compare performance characteristics in the interpretation of EUS FNA/FNB samples between AI and ROSE. Procedures to be used Eligible patients will undergo EUS guided FNA/FNA of PSLs using standard of care. Sample slides are prepared by a cytopathologist at bedside and observed under a microscope. At the same time, the slides are scanned using a slide scanner and those images are saved for interpretation by AI at a later time.
CONDITIONS
Official Title
Artificial Intelligence (AI) Cytopathology Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have EUS finding of a PSL
- Do not have contraindications for FNA/FNB
You will not qualify if you...
- Inability to provide informed consent for the procedure
- Contraindication for FNA/FNB eg coagulopathy, lack of avascular window for FNA
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Memorial Hermann Hospital
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
P
Prithvi B Patil, MS
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here